what startups were up to two weeks ago
Dermavant Sciences Raises $200M in Funding
Dermavant Sciences, a Long Beach CA, Durham, NC, and Basel, Switzerland-based biopharmaceutical company which specializes in immunodermatology therapy, raised $200M in funding.
The company intends to use the funding proceeds for the payment of certain one-time milestone obligations that become payable upon the approval and commercialization of tapinarof for the treatment of psoriasis in the United States, as well as for other general corporate purposes.
Led by Todd Zavodnick, Chief Executive Officer, Dermavant, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. The company’s medical dermatology pipeline includes both late-stage and earlier-stage-development product candidates to address important immuno-dermatological conditions, including psoriasis, atopic dermatitis, vitiligo, primary focal hyperhidrosis, and acne.
Dermavant Sciences Raises $200M in Funding | FinSMEs
Dermavant Sciences, a Long Beach CA and Basel, Switzerland-based biopharmaceutical company which specializes in immunodermatology therapy, raised $200M in funding
Alentis Therapeutics Raises $67M in Series B Financing
Alentis Therapeutics, a Basel, Switzerland biotech developing treatments for fibrotic diseases, raised USD67 (CHF60)m in Series B financing round.
The round was led by Morningside Venture Investments, joined by Jeito Capital and Series A investors BioMed Partners, BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund, High-Tech Gründerfonds and Schroders Capital. In conjunction with the funding, Jason Dinges of Morningside and Rafaèle Tordjman, founder and CEO of Jeito Capital, joined Alentis’ Board of Directors.
The company intends to use the funds for proof-of-concept clinical trials of its first in class, Claudin-1 targeting, anti-fibrotic molecules in advanced liver and kidney fibrosis, and support ongoing drug discovery programs targeting other fibrotic diseases and hepatobiliary cancers.
Founded in 2019 based on research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm) and led by Dr. Roberto Iacone, CEO, Alentis Therapeutics is a biotech company that focuses on developing new treatments for fibrotic diseases. The company’s lead candidates are monoclonal antibodies that are highly selective for Claudin-1, a novel, previously unexploited target with a unique mechanism of action that plays a key role in the pathology of liver fibrosis and fibrosis-driven hepatobiliary cancers. It also has early discovery programs exploring the potential of Claudin-1 inhibition in the treatment of fibrosis of other tissues including the kidney and lung.
Alentis Therapeutics Raises $67M in Series B Financing | FinSMEs
Alentis Therapeutics, a Basel, Switzerland biotech developing treatments for fibrotic diseases, raised USD67 (CHF60)m in Series B financing round
Ecommerce software Circuly receives 1.3 million
The Bielefeld startup Circuly has raised 1.3 million euros in a seed financing round.
The VC Neoteq Ventures, the technology fund OWL and business angels from the retail sector have invested. Existing investors, including Cologne-based VC Venista Ventures, are also injecting capital.
Circuly was founded in April of this year by Victoria Erdbrügger and Nick Hujis. The startup is developing a SaaS tool that e-commerce companies can use to rent out their products in addition to traditional sales. Fahrrad.de and Tier Mobility are said to already be part of the start-up’s customer base.
E-Commerce-Software Circuly erhält 1,3 Millionen | GS Startup-Ticker - Business Insider
Alles, was man über Startups wissen muss. Auf einen Blick. Die Kurznachrichten aus der Szene könnt ihr hier verfolgen.
Iksuda Therapeutics Raises $47M in Funding
Iksuda Therapeutics, a Newcastle UK-based company focused on developing antibody drug conjugates (ADCs), raised $47M in funding.
The round was co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners.
The company intends to use the funds to accelerate clinical progression of its pipeline of new generation of antibody drug conjugates, targeting tumours with high unmet need.
Led by Dr Dave Simpson, Chief Executive Officer, Iksuda Therapeutics is the developer of a new generation of antibody drug conjugates (ADCs). Its ADC programmes target tumours that currently have limited treatment options and high relapse rates. Its lead pre-clinical candidate, IKS03, is a CD19-targeted ADC candidate for B-cell cancers.
Iksuda Therapeutics Raises $47M in Funding | FinSMEs
Iksuda Therapeutics, a Newcastle UK-based company focused on developing antibody drug conjugates (ADCs), raised $47M in funding
Finnish telehealth company Medixine raises €2.9 million, supports healthcare workers through data-driven resource allocation
Finland-based Medixine has raised €2.9 million in a crowdfunding campaign organized by Springvest. This capital adds on to the €3.2 million Medixine has already raised over three rounds from investors including the Finnish Innovation Fund Sitra and Vendep Capital. The firm reports that the new funds will be used to propel international presence, particularly in the UK and Central Europe, and further develop new offerings within the Medixine Suite.
Medixine was founded in 2000 by Dr. Tapio Jokinen, and started out life as a consultancy company. Today, the Medixine Suite offers a communication, monitoring and collaboration platform for healthcare workers. With video appointments, a secure chat function, secure messaging, health questionnaires, remote health monitoring, and automated screening features, Medixine seeks to lighten the load for overworked doctors, nurses, and associated support professionals.
Finnish telehealth company Medixine raises €2.9 million, supports healthcare workers through data-driven resource allocation – Tech.eu
Finland-based Medixine has raised €2.9 million in a crowdfunding campaign organized by Springvest. This capital adds on to the €3.2 million Medixine has already raised over three rounds from investors […]
Brinter Raises €1.2M in Seed Funding
Brinter, a Turku, Finland-based bioprinting startup, closed a €1.2M seed funding round.
The round was led by early-stage VC Innovestor.
The company will use the capital to further expand its operations internationally in Europe and the US.
Founded in 2020 via partial demerger in Turku, Finland, and led by CEO Tomi Kalpio, Brinter is a modular multi-material bioprinting platform scalable from manual R&D to automated production. The company works with science and bioengineering organizations to integrate 3D bioprinting into their research, manufacturing, and treatment methods. Brinter is active in over 10 countries and serves organizations such as Nanoform, as well as research organizations like VTT, BEST group at the University of Glasgow, Johannes Gutenberg University of Mainz, the University of Oulu, and the University of Helsinki.
Brinter Raises €1.2M in Seed Funding | FinSMEs
Brinter, a Turku, Finland-based bioprinting startup, closed a €1.2M seed funding round. The round was led by early-stage VC Innovestor.
Lyra Health Raises $200M in Funding
Lyra Health, a Burlingame CA-based company which specializes in comprehensive mental health care benefits, raised $200M in funding.
The round was led by Coatue joined by new investor Sands Capital, along with existing investors.
With the new funding, the company plans to accelerate the delivery of its benefits for companies with employees located around the world and enhance its international solutions.
Led by David Ebersman, CEO and co-founder, Lyra Health is a provider of comprehensive mental health care benefits for multinational companies, including eBay; Genentech, a member of the Roche Group; Uber; and VCA Animal Hospitals. Lyra provides evidence-based care that supports people across all facets of mental health, from wellness and preventive care to the most severe conditions. Its Blended Care Therapy pairs video counseling sessions, one-to-one messaging, and digital activities prescribed by the provider to support individuals in their everyday lives. Based on Cognitive Behavioral Therapy principles, this treatment model with ongoing support between sessions helps individuals improve faster. Lyra’s curated network includes more than 5,000 coaches, therapists, and doctors in the U.S., with an additional 85,000 providers available worldwide through global partnerships.
Lyra Health Raises $200M in Funding | FinSMEs
Lyra Health, a Burlingame CA-based company which specializes in comprehensive mental health care benefits, raised $200M in funding
Cerebral Raises $127M in Series B Funding
Cerebral, Inc., a San Francisco, CA-based online provider of psychiatric and behavioral therapy services, received $127m in Series B funding.
The round was led by Access Industries, joined by WestCap, Silver Lake Waterman, Artis Ventures, Bill Ackman, Oak HC/FT, Chris Burch, AirAngels, and others.
Led by Founder and CEO Kyle Robertson, Cerebral has introduced medication management and behavioral health services to every state in the U.S. and is able to provide therapy services to over 70% of the population. The company also debuted its mobile app, launched digital cognitive behavioral therapy (CBT), and introduced in-network insurance coverage. Cerebral has over 2,000 team members and continues to scale.
The company intends to use the funds to further expand its services and products, add several new mental health verticals to its treatment offerings, which already include anxiety, depression, insomnia, ADHD, and more. Cerebral will also add group therapy to its services.
Cerebral Raises $127M in Series B Funding | FinSMEs
Cerebral, Inc., a San Francisco, CA-based online provider of psychiatric and behavioral therapy services, received $127m in Series B funding
Senda Biosciences Closes $98M Series B Financing
Senda Biosciences, a Cambridge, Mass.-based company that harnesses the molecular interactions between humans, plants, and bacteria to develop new types of medicines, raised a $55m Series B extension financing, bringing its total Series B funding to $98m and total funding raised to date to $143m.
Flagship Pioneering, Senda’s founder, participated along with new investors including Longevity Vision Fund, Terra Magnum Capital Partners, Mayo Clinic, Partners Investment and Mint Venture Partners. Current investors Alexandria Venture Investments and State of Michigan Retirement System also participated.
Proceeds from the financing will be used to advance the development of the company’s platform and its therapeutic programs into clinical trials.
Led by Guillaume Pfefer, Ph.D., Chief Executive Officer, and Scott Plevy, M.D., Chief Scientific Officer, Senda Biosciences is systematically harnessing the molecular interactions that have evolved over millennia between humans, plants, and bacteria to develop new types of medicines. The company’s platform enables the deployment of proteins or genetic material throughout the body, tunable modulation of the immune system, and precise intervention at the point of interaction between human and non-human species.
Senda Biosciences Closes $98M Series B Financing | FinSMEs
Senda Biosciences, a Cambridge, Mass.-based company that harnesses the molecular interactions between humans, plants, and bacteria to develop new types of medicines, raised a $55m Series B extension financing
HiFiBiO Therapeutics Closes $75M Series D Financing
HiFiBiO Therapeutics, a Cambridge, Massachusetts-based multinational biotechnology company with expertise in immune modulation and drug intelligent science, closed a $75M Series D financing round.
The round was led by the new investor Mirae Asset Financial Group with participation from Further, B Capital Group, Sherpa, Maison Capital, Trinity Innovation Fund, Grand Mount, and HKSTP Venture Fund and existing shareholders IDG, Sequoia, Legend Star, and Hengxu. With the new round, Ryan Jeong from Mirae Asset Capital will be joining the company’s Board of Directors.
The company intends to use the funds to advance two lead antibody oncology assets into Phase I clinical trials – HFB200301, a novel anti-TNFR2 antibody and HFB301001, a differentiated second generation anti-OX-40 antibody.
Led by Liang Schweizer, PhD, President and CEO, HiFiBiO Therapeutics is a multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company has laboratories in three continents in Cambridge, Mass., Paris, France, Shanghai, Hong Kong, and Hangzhou in China.
HiFiBiO Therapeutics Closes $75M Series D Financing
HiFiBiO Therapeutics, a Cambridge, Massachusetts-based multinational biotechnology company with expertise in immune modulation and drug intelligent science, closed a $75M Series D financing round
Transcarent Raises $58M in Series B Funding
Transcarent, a San Francisco, CA-based consumer-directed health and care experience for employees of self-insured employers and their families, raised $58m in Series B funding.
The round, which brought total funding to $98m, was led by General Catalyst and 7wireVentures, with participation from Merck Global Health Innovation Fund, Kleiner Perkins, Leaps byBayer, GreatPoint Ventures, and Threshold Ventures along with existing investors Alta Partners and Jove Equity Partners.
The company intends to use the funds to expand its risk-based offering for self-insured employers.
Launched in March 2021 by Glen Tullman, CEO, Transcarent is a health and care experience company that delivers a personalized, 24/7 care experience, addressing virtually all of the most common and most challenging issues a person faces by connecting them with a personal Health Guide or physician, offering expert second opinions, medication review and management, virtual physical therapy, and comprehensive appropriate site-of-care surgery solutions.
Transcarent Raises $58M in Series B Funding | FinSMEs
Transcarent, a San Francisco, CA-based consumer-directed health and care experience for employees of self-insured employers and their families, raised $58m in Series B funding
Texas Original Compassionate Cultivation Raises $21M in Series B Funding
Texas Original Compassionate Cultivation (TOCC), an Austin TX-based medical cannabis company, raised $21M in Series B funding.
The round was led by AFI Capital Partners.
The company intends to use the funds to bolster production and expand statewide.
Led by Morris Denton, CEO, TOCC is a licensed medical marijuana producer in Texas, working alongside physicians to provide cannabis medicine to patients and families seeking relief across the state.
Texas Original Compassionate Cultivation Raises $21M in Series B Funding
Texas Original Compassionate Cultivation (TOCC), an Austin TX-based medical cannabis company, raised $21M in Series B funding
Kurome Therapeutics Closes $15M in Series A Funding
Kurome Therapeutics, a Cincinnati OH-based-developer of therapies that target adaptive resistance mechanisms in cancer, raised $15M in Series A funding. The round was led by Medicxi and Affinity Asset Advisors with participation from founding investor CincyTech, and other existing seed investors. Aaron Kantoff, Venture Partner at Medicxi, and Daniel Heller, General Partner and Chief Investment Officer at Affinity Asset Advisors, will join the Kurome Therapeutics Board of Directors.
Led by Jan Rosenbaum, Ph.D., chief executive officer and chief scientific officer, Kurome Therapeutics is a preclinical stage company dedicated to developing novel therapies that target adaptive resistance mechanisms in cancer cells while inhibiting critical disease modifying genes.
Kurome Therapeutics Closes $15M in Series A Funding | FinSMEs
Kurome Therapeutics, a Cincinnati OH-based-developer of therapies that target adaptive resistance mechanisms in cancer, raised $15M in Series A funding
EvoEndo Raises $10.1M in Funding
EvoEndo, Inc., a Denver CO-based preclinical medical device company which specializes in developing systems for unsedated Transnasal Endoscopy (TNE), raised $10.1M in funding.
The Backers were undisclosed.
The company intends to use the funds to advance its technology.
Co-founded in 2017 by Dr. Joel Friedlander and led by Heather Underwood, Chief Executive Officer, EvoEndo is developing technology to help physicians diagnose, treat, and monitor conditions for a variety of gastrointestinal disorders. The system combines sterile, single-use, flexible endoscopes with VR-based patient distraction to allow the procedure to be performed safely in children and adults without anesthesia or sedation. The company is led by Heather Underwood, PhD, an experienced medical device and technology entrepreneur, and alumna of the Stanford University Biodesign Program.
EvoEndo Raises $10.1M in Funding
EvoEndo, Inc., a Denver CO-based preclinical medical device company which specializes in developing systems for unsedated Transnasal Endoscopy (TNE), raised $10.1M in funding
Heartseed Raises $37M in Series C Funding
Heartseed, a Tokyo, Japan-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), raised 4 Billion-yen (approx. $37M) in Series C funding.
The round brought its total financial backing to 8.2 Billion yen (approx. $75M) since its foundation in 2015.
New investors are UTokyo Innovation Platform Co. (UTokyo IPC), Medical Incubator Japan, Keio Innovation Initiative (KII), and Sumitomo Mitsui Trust Investment. Among the existing investors, SBI Group, Nissay Capital, SMBC Capital, Medipal Holdings, and Itochu Chemical Frontier participated in this round.
The company intends to use the funds to accelerate the initiation of global clinical trial of HS-001 for HF as well as to confirm its proof of concept in Phase 1/2 LAPiS study in Japan, and examine a less invasive administration such as transendocardial injection using a catheter.
Led by Professor. Keiichi Fukuda, co-founder and CEO, Heartseed is advancing HS-001, an allogeneic iPSC-derived, highly purified ventricular cardiomyocyte spheroids. By forming micro-tissue-like spheroids, retention rate and viability of cell transplant are improved. The spheroids are transplanted using a special administration needle (SEEDPLANTER®) and guide adapter developed for safe and efficient administration of the spheroids into the myocardial layer of the heart.
Heartseed Raises $37M in Series C Funding
Heartseed, a Tokyo, Japan-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), raised 4 Billion-yen (approx. $37M) in Series C funding
ViAqua Therapeutics Raises $4.3M in Funding
ViAqua Therapeutics, a Misgav, Israel-based biotechnology RNA-particle platform promoting and improving animal health in aquaculture, raised $3.4 in funding.
The round was led by S2G Ventures (S2G Oceans & Seafood Fund), Thai Union, and Agriline. Earlier investors Nutreco, Visvires New Protein, The Trendlines Group (SGX:42:T;OTCQX: TRNLY) and the Technion Israel Institute of Technology also participated in this round.
The company intends to use the capital for the commercialization of the first product for health for shrimp and the development of additional products for aquatic animal health and nutrition.
Led by Shai Ufaz, CEO, ViAqua Therapeutics is a biotechnology company and developer of an orally administered RNA-particle platform to promote and improve animal health in aquaculture. Using RNA and an encapsulated delivery method, the company will promote shrimp health in the face of viral challenges, including prevalent and devastating diseases which are widespread in shrimp.
